IMAGIN MEDICAL

Innovating Prostate & Bladder Cancer Treatment

enCAGE™ Therapy for Prostate Cancer

i/Blue™ Visualization for Bladder Cancer

Q3 2023

Forward-Looking Statements

These materials may contain forward-looking statements relating to the business of Imagin Medical (the “Company” or “Imagin”) including with respect to the progress, timing and completion of the Company’s research, development, and clinical trials for product candidates, the Company’s ability to manufacture, market, commercialize, partner and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Company’s estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements, and its needs for additional financing, and any M&A timelines. Even if the Company’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company’s results or developments in the future. In some cases, you can identify forward-looking statements by words such as “could”, “should”, “may”, “expect”, “anticipates”, “believes”, “intends”, “estimates”, or similar words. These forward-looking statements are based largely on the Company’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements express or implied by these forward-looking statements. In particular, the Company’s expectations could be affected by, among other things, uncertainties involved in the development and manufacture of medical devices, unexpected results, unexpected regulatory actions or delays, competition in general, the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will, in fact, be realized, and no representation or warranty is given as to the completeness or accuracy of the forward-looking statements contain in these materials.

Imagin is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Imagin* Business Overview

Innovating Prostate & Bladder Cancer Treatment

- Disruptive products will dramatically improve prostate & bladder cancer treatment
- Option for hospital or physician office treatment improves economics for providers & increases the addressable market
- Over $1B addressable market
- Development risk mitigated
- 11 issued patents
- Previously successful management team



PROSTATE CANCER

enCAGE Precision Ablation Therapy

Minimizes Erectile Dysfunction and Urinary Incontinence

BLADDER CANCER

i/Blue Imaging System

Dramatically improves visualization, 33% more tumors found, recurrence rates reduced

* Imagin Medical, Inc. is a development stage company with one 510(k) and does not currently have any other Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction.

Prostate Cancer

U.S. Market Data

- 1 out of 7 men will be diagnosed
- 3.1M living with prostate cancer
- Over 268K new cases/year
- Over 34K deaths/year
- $5-$8B/year metastatic prostate cancer cost to Medicare, billions more for initial treatments

Prostate Cancer most prevalent cancer in men in the U.S.

Number 2 cancer deaths for men

enCAGE - New Standard of Care for Prostate Cancer

Today's Standards of Care

Surgery

Radiation

Focal Therapy

Today's Challenges:

- Important nerves immediately adjacent to tumors can be damaged during every current modality
- Difficulty in controlling the treatment beyond the margins of the tumor
- Erectile dysfunction and urinary incontinence are frequent side effects in these modalities

The New Standard of Care: enCAGE Therapy

- enCAGE Coil creates a Faraday Cage effect "walling off" the delicate structures
- Radio Frequency (RF) energy within the coil targets only the tumor
- Erectile & urinary function are unimpaired
- Minimizes future costs to the healthcare system

Faraday Cage Effect

enCAGE Control



enCAGE Coil Disposable Kit & Generator

Electrodes, Introducer and Guide Template

enCAGE Coil Electrode

8mm, 10mm, 12mm & 14mm

Introducer

Enables better targeting of electrode

Guide Template



Facilitates movement of electrode from ablation to ablation

Works with…

Imagin enCAGE RF Generator



Automated control based on impedance monitoring

**Works with commercially available Navigation Systems*

Imagin Medical enCAGE Therapy Study

20 patients evaluated at University College London. Mark Emberton M.D. & Clement Orczyk M.D.

The clinical data was excellent, although the device used was, essentially, a prototype device.

Following is an excerpt from an editorial comment in *The Journal of Urology*:

> *"Coil RFA with the enCAGE device is a unique option for focal prostate ablation. With transperineal insertion, and ablation limited to the coil cage, treatments can be applied to both anterior and posterior lesions with minimal chance of ablating nearby vital structures.*
>
> *In this series of 20 men with intermediate risk prostate cancer, no grade 3-5 adverse events were reported, and 15 men had complete absence of any cancer at the 6-month biopsy. This is impressive considering that it was the first of its kind experience and post-treatment biopsy was mandated and thorough, with a median of 6 cores from the treatment site, which is beyond the approach of most focal therapy series. The success may in large part be due to the ingenious approach of adding extra needles to pull the energy outside the coil…"*

* Results published in AUA Journal of Urology, April 2021.

enCAGE Coil FDA Strategy

FDA Status

- 510(k) clearance for general soft tissue ablation
- Tissue ablation, as a specific indication for prostate ablation requires FDA clearance under Class 11 De Novo
- Pre-Submission meeting with FDA, approved enCAGE DeNovo clinical study plan

FDA Action

- Submit Special 510(k) for refined enCAGE for soft tissue indication
- Submit formal applications for prostate labeling when verification testing is complete

i/Blue™ Imaging System
for Bladder Cancer

Current Systems vs. Imagin i/Blue

Corrects Limitations of Today's Blue Light

Current
Blue Light Equipment

VS

i/Blue
Imaging System



Exceptional Clinical & Economic Value Proposition

- Enables physician to **view two images on one screen** vs having to switch back and forth, improving clinical results
- i/Blue **miniaturizes and consolidates** 3 key components into one state-of-the-art optical system
- Leads to significantly **reduced manufacturing costs** leading to higher margins
- **i/Blue works with scopes already owned by the hospital** seamlessly into work protocol, and adds additional saving

Imagin* Business Overview

Who We Are

Management Team

Jim Hutchens President & CEO	Boston Scientific	Smith+Nephew	**Venture Capital Early-Stage**
John Vacha, CPA CFO	Deloitte & Touche	intact™ (sold to Medtronic)	
Mike Vergano Director of Operations	Boston Scientific	**Corning Diagnostic**	**Microsurge** (all phases of project management)
Sheila Heyer, J.D. Consultant QA/RA	Boston Scientific	FDA	

World Class Medical Advisors & SAB

- Mark Emberton, MD, University College London
  Dean of faculty, Professor of Interventional Oncology, 500 peer reviewed papers, leading focal therapy proponent
- Ashish Kamat, MD, MD Anderson Cancer Center
  Professor of Urological Oncology, 300 peer reviewed papers, Expertscape rated #1 in bladder cancer

* Imagin Medical, Inc. is a development stage company and does not currently have any Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction.

IMAGIN MEDICAL

Thank You!

CONTACT INFORMATION:

Jim Hutchens
President & CEO
(617) 571-6006
jhutchens@imaginmedical.com

John Vacha
CFO
(617) 448-8379
jvacha@imaginmedical.com